Serum miR-22 as potential non-invasive predictor of poor clinical outcome in newly diagnosed, uniformly treated patients with diffuse large B-cell lymphoma: an explorative pilot study

Table 4 Pathways significantly enriched in miR-22 targets

Term	Genes	p-value
hsa05214:Glioma	CDKN1A, CDK6	0.018
hsa04115:p53 signaling pathway	CDKN1A, CDK6	0.019
hsa05218:Melanoma	CDKN1A, CDK6	0.02
hsa05220:Chronic myeloid leukemia	CDKN1A, CDK6	0.02
hsa04066:HIF-1 signaling pathway	CDKN1A, TFRC	0.028
hsa04110:Cell cycle	CDKN1A, CDK6	0.035
hsa05161:Hepatitis B	CDKN1A, CDK6	0.041

ISSN: 1756-9966